|
Research article summary:
Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study.
Abstract Extract:
Frontotemporal dementia (FTD) represents an important cause for degenerative disruption and is increasingly recognized as an important cause (up to 25%) of degenerative dementia among late-middle-age individuals. The serotoninergic system is tightly ... (Full abstract text below) Published 2003
in Journal: Eur Neurol
(Language : eng)
Full Pubmed Extract
This information was retrieved, real-time, on your behalf from the public area of the Pubmed website:
1. Eur Neurol.
2003 ;49(1):13-9
Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study.
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A
Dipartimento di Fisiologia e Patologia, UCO di Neurologia, Università di Trieste, Italia. moretti@univ.trieste.it
Frontotemporal dementia (FTD) represents an important cause for degenerative disruption and is increasingly recognized as an important cause (up to 25%) of degenerative dementia among late-middle-age individuals. The serotoninergic system is tightly bound to frontal circuits, whose degeneration subserves FTD. Patients aged 64-68 years, with a diagnosis of FTD, were randomized to receive paroxetine up to 20 mg/day (n = 8) or piracetam up to 1,200 mg/day (n = 8). At 14 months, the patients treated with paroxetine showed significant improvements in behavioral symptoms, reflected by a reduction of caregiver stress. Side effects were easily tolerable, and there was no dropout. The results are presented with an overview of the literature on the topic.
PMID : 12464713 [PubMed - Indexed for MEDLINE]
This information is obtained from the National Library of Medicine (NLM). Abstract text and other information may be subject to copyright. Type "NLM copyright" into Google for more information.
Full Author Information
| First Name | LastName | Initials |
| Rita | Moretti | R |
| Paola | Torre | P |
| Rodolpho M | Antonello | RM |
| Giuseppe | Cazzato | G |
| Antonio | Bava | A |
Affiliation: Dipartimento di Fisiologia e Patologia, UCO di Neurologia, Università di Trieste, Italia. moretti@univ.trieste.it
3rd Party provider links
Click the links below to go to related 3rd party information:
MESH categories and related page links
This article was linked to the MESH categories shown on the left below. The links on the right are related Memletics pages.
Category links from this article:- Aged
- Caregivers - psychology
- Cost of Illness
- Dementia - diagnosis, drug therapy, psychology
- Female
- Humans
- Male
- Mental Status Schedule
- Middle Aged
- Neuropsychological Tests
- Paroxetine - adverse effects, therapeutic use
- Piracetam - adverse effects, therapeutic use
- Serotonin Uptake Inhibitors - adverse effects, therapeutic use
- Social Behavior Disorders - diagnosis, drug therapy, psychology
| | Related Memletics topics: |
Links for this articleFor links to places where you can get the full text of this article see links. Note there may be a subscription or fee required for access to the full text. New! Using similar technology to this site, we have launched find-health-articles.com, targeting over 1 million health research article abstracts. Related ArticlesHere are some articles related to this one (by title keywords): Keywords in this article:age, aged, behavioral, bound, caregiver, cause, circuits, day, degeneration, degenerative, dementia, diagnosis, disruption, dropout, easily, effects, frontal, frontotemporal, ftd, important, improvements, increasingly, individuals, late, literature, middle, months, overview, paroxetine, patients, piracetam, presented, randomized, receive, recognized, reduction, reflected, represents, results, serotoninergic, side, significant, stress, subserves, symptoms, system, tightly, tolerable, treated, whose, years
|
